To explore how Musashi-2 affects tumor immune infiltration, we focused on the profiles of key immune inhibitors in ccRCC, and the relationships between Musashi-2 and immune inhibitors in 607 cases of ccRCC were evaluated. This evidence concerns the gene MSI2 and nonpapillary renal cell carcinoma.